Anika Therapeutics (ANIK) Cash & Equivalents (2010 - 2026)

Anika Therapeutics (ANIK) has reported Cash & Equivalents for 17 consecutive years, with $38.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 27.75% year-over-year to $38.4 million in Q2 2026; TTM through Jun 2026 was $38.4 million, a 27.75% decrease from a year earlier, with the FY2025 full-year figure at $57.5 million, up 3.33% from the prior year.
• Cash & Equivalents was $38.4 million for Q2 2026 at Anika Therapeutics, down from $41.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $91.4 million in Q2 2022 and troughed at $38.4 million in Q2 2026.
• A 5-year average of $66.2 million and a median of $63.9 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents dropped 28.8% in 2023 and rose 3.33% in 2025, its largest moves.
• Over 5 years, Cash & Equivalents stood at $86.3 million in 2022, then fell by 20.37% to $68.7 million in 2023, then fell by 19.07% to $55.6 million in 2024, then grew by 3.33% to $57.5 million in 2025, then tumbled by 33.17% to $38.4 million in 2026.
• The last three Cash & Equivalents figures came in at $38.4 million (Q2 2026), $41.0 million (Q1 2026), and $57.5 million (Q4 2025), per Business Quant data.